Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioCentriq's $29.2M in Funding to Enhance Cell Therapy Services | Contract Pharma

What are you searching for?

Sign in
Breaking News

BioCentriq’s $29.2M in Funding to Enhance Cell Therapy Services

Will further accelerate capabilities to provide end-to-end services for cell therapy development and manufacturing.

By: Anthony Vecchione

BioCentriq, a global cell-based therapy contract development and manufacturing organization (CDMO), reported the successful completion of its latest round of fundraising, securing $29.2 million to accelerate delivery of cell therapies by translating, optimizing, and scaling processes for GMP manufacture.

With this capital, BioCentriq will further accelerate its capabilities to provide end-to-end services for cell therapy development and manufacturing. The funds will be used to enhance BioCentriq’s state-of-the-art facilities, invest in advanced technologies, and expand its team of experts to meet the increasing demand for scalable cell therapy services.

“We are thrilled to announce the successful completion of our latest fundraising round, which reflects the confidence of our investors in BioCentriq’s vision and capabilities,” said James Park, BioCentriq Interim CEO and Chairman of the Board. “This capital injection positions us strongly to continue driving innovation in cell therapy development, enabling our partners to bring transformative treatments to patients around the world.”

The company’s services include process development, manufacturing, and analytical testing to help ensure seamless and efficient development of cell-based therapies for diverse therapeutic areas.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics